Prise en charge de l'hépatite C chronique : les dernières avancées thérapeutiques

Protease inhibitors (AMM 2011: telaprevir and boceprevir), in combination with pegylated bitherapy, increase the rate of sustained virologic response and, in some cases, reduce the duration of treatment to 6 months. Other molecules targeting different stages of HCV replication are being evaluated, sometimes associated with each other in trials without interferon. The development of specific antivirals marks a major turning point in the treatment of chronic hepatitis C and opens the door to new, more effective and better tolerated therapeutic combinations, with or without interferon. Treatment recommendations should evolve, indicating the therapeutic strategies best suited for each patient category. Therapeutic education will play an important role in optimizing patient care.